PHASE II STUDY OF THE TOLERABILITY OF ADJUNCTIVE AZACITIDINE IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA.

Trial Profile

PHASE II STUDY OF THE TOLERABILITY OF ADJUNCTIVE AZACITIDINE IN PATIENTS UNDERGOING REDUCED INTENSITY ALLOGENEIC STEM CELL TRANSPLANTATION FOR ACUTE MYELOID LEUKAEMIA AND MYELODYSPLASIA.

Completed
Phase of Trial: Phase II

Latest Information Update: 08 Jun 2016

At a glance

  • Drugs Azacitidine (Primary)
  • Indications Acute myeloid leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Acronyms RICAZA
  • Most Recent Events

    • 31 May 2012 United Kingdom Clinical Research Network reports accrual to date changed from 150% to 170%.
    • 19 Jan 2012 Actual end date (May 2011) added as reported by ISRCTN: Current Controlled Trials.
    • 19 Jan 2012 Status changed from recruiting to completed as reported by ISRCTN: Current Controlled Trials.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top